Cingulate Inc. (CING): Cash & Equivalents
$10.95M
As of 2025-12-31
$28.40M
As of 2026-06-30
+26.9%
3-year compound annual growth
+55.7%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $10.95M | -10.3% | 2026-03-18, Balance as of period end |
| 2024-12-31 | $12.21M | n/m | 2026-03-18, Balance as of period end |
| 2023-12-31 | $52.4K | -99.0% | 2025-03-27, Balance as of period end |
| 2022-12-31 | $5.36M | -67.5% | 2024-04-01, Balance as of period end |
| 2021-12-31 | $16.49M | n/m | 2023-03-10, Balance as of period end |
| 2020-12-31 | $1.20M | n/a | 2022-03-28, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Cingulate Inc. (CING) | 2025-12-31 | $10.95M | -10.3% |
| Cellectar Biosciences, Inc. (CLRB) | 2025-12-31 | $13.20M | -43.3% |
| Synlogic, Inc. (SYBX) | 2025-12-31 | $14.67M | -22.2% |
| Reviva Pharmaceuticals Holdings, Inc. (RVPH) | 2025-12-31 | $14.44M | +7.1% |
| Aprea Therapeutics, Inc. (APRE) | 2025-12-31 | $14.60M | -36.1% |
| Biovie Inc. (BIVI) | 2026-06-30 | $8.98M | -48.8% |
| Anixa Biosciences Inc (ANIX) | 2025-10-31 | $1.24M | -2.1% |
| Actuate Therapeutics, Inc. (ACTU) | 2025-12-31 | $13.16M | +52.3% |
| CytoDyn Inc. (CYDY) | 2026-05-31 | $11.85M | -0.4% |
Compare CING, CLRB, SYBX, RVPH side by side · Screen every company in Pharmaceutical Preparations ↗